Page 16 - Guideline

09010:Layout 1 3/18/10 9:26 PM Page E34

Wood et al.

8. Richie JP. Impact of diagnostic delay in testis cancer: Results of a large population-based study: Huyghe
data using TIP, and reserve the transplant for third line.
E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P, Human Fertility
For patients undergoing HDCT, high dose carboplatin Research Group, Paule de Viguier Hospital, Toulouse University III, France; Urology and Andrology
and etoposide regimen is the conditioning regimen of choice. Department, Paule de Viguier Hospital, Toulouse, France. Urol Oncol 2008;26:220-1.
th
High-dose chemotherapy and transplantation could be 9. Sobin LH, Wittekind CH, eds. TNM classification of malignant tumours (UICC). 6 ed. Hoboken, NJ:
offered as third-line therapy. Wiley, John & Sons; 2002.
10. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic
Patients who relapse after standard dose and high-dose
germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
chemotherapy should be offered third-line treatment as long- 11. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous
term disease control may still be achieved. metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818-26.
Salvage surgery should always be considered in patients 12. Winstanley AM, Mikuz G, Debruyne F, et al. Handling and reporting of biopsy and surgical specimens of
with residual resectable disease. testicular cancer. Eur Urol 2004;45:564-73.
13. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. Apmis 2003;111:76-83;
Patients with late relapse (nonseminoma) should have
discussion 83-75.
surgical resection of disease if possible. 14. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in
Patients with mediastinal primary GCT who relapse should 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer
rarely if ever be offered transplantation. Group (GG). Eur Urol 2002;42:553-62; discussion 562-3.
15. Horwich A, Alsanjari N, A’Hern R, et al. Surveillance following orchidectomy for stage I testicular semi-
†
* Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Department noma. Br J Cancer 1992;65:775-8.
‡
of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC; Division of Urology, University 16. Oliver R, Boubilkova L, Ong J. Fifteen-year follow-up of the Anglian Germ Cell Cancer group adjuvant
studies of carboplatin as an alternative to radiation or surveillance for stage 1 seminoma. Proc ASCO
§
Health Network, University of Toronto, Toronto, ON; Department of Radiation Oncology, Radiation 2001;19Abstract 780.
±
Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON; Division of 17. Ramakrishnan S, Champion AE, Dorreen MS, et al. Stage I seminoma of the testis: is post-orchidectomy sur-
¥
Medical Oncology, Juravinski Cancer Centre, Hamilton, ON; Department of Medical Imaging, veillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) 1992;4:284-6.
#
University Health Network, University of Toronto, Toronto, ON; Department of Pathology, University 18. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I semino-
β
Health Network, University of Toronto, Toronto, ON; Department of Medicine, London Health ma of the testis. Eur J Cancer 1993;29A:1931-4.
α
Sciences Centre, London, ON; Department of Medical Oncology, Cross Cancer Institute, Edmonton, 19. Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I
µ
Δ
AB; Department of Radiation Oncology, Vancouver Cancer Clinic, Vancouver, BC; Division of seminoma? J Clin Oncol 2005;23(16suppl):4520.
**
Medical Oncology, McGill University Health Centre, Montréal, QC; Department of Medicine, 20. Tyldesley S, Voduc D, McKenzie M, et al. Surveillance of stage I testicular seminoma: British Columbia
Cancer Agency Experience 1992 to 2002. Urology 2006;67:594-8.
††
Division of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON; Department 21. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by
‡‡
of Medicine, University of Toronto, Princess Margaret Hospital, Toronto, ON; Department of surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52.
§§
Urology, Charité – Universitätsmedizin, Freie Universität Berlin, Berlin; Academic Radiotherapy, 22. Aparicio J, Germa JR, Garcia del Muro X, et al. Risk-adapted management for patients with clinical
±±
Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey; Oregon Health & stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol
Science University Cancer Institute, Portland, OR 2005;23:8717-23.
23. Bayens YC, Helle PA, Van Putten WL, et al. Orchidectomy followed by radiotherapy in 176 stage I and II
testicular seminoma patients: benefits of a 10-year follow-up study. Radiother Oncol 1992;25:97-102.
Competing interests: None declared. 24. Coleman JM, Coleman RE, Turner AR, et al. The management and clinical course of testicular semino-
ma: 15 years’ experience at a single institution. Clin Oncol (R Coll Radiol) 1998;10:237-41.
25. Fossa SD, Bokemeyer C, Gerl A, et al. Treatment outcome of patients with brain metastases from malig-
This paper has been peer-reviewed. nant germ cell tumour s. Cancer 1999;85:988-97.
26. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of
stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for
the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-8.
References 27. Santoni R, Barbera F, Bertoni F, et al. Stage I seminoma of the testis: a bi-institutional retrospective
analysis of patients treated with radiation therapy only. BJU Int 2003;92:47-52; discussion 52.
1. International Agency for Reseach on Cancer. World Health Organization. Available at: http://www- 28. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradi-
dep.iarc.fr/. Accessed March 9, 2010. ation and surveillance. J Clin Oncol 1995;13:2255-62.
2. McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumour s in 29. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma:
the United States. Cancer 2003;97:63-70. A Medical Research Council randomized trial. Medical Research Council Testicular Tumour Working
3. Canadian Cancer Society. Available at: www.cancer.ca. Accessed March 17, 2010. Group. J Clin Oncol 1999;17:1146.
4. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with 30. Logue JP, Harris MA, Livsey JE, et al. Short course paraaortic radiation for stage I seminoma of the
“poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of testis. Int J Radiat Oncol Biol Phys 2003;57:1304-9.
Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular 31. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treat-
Cancer Working Party. J Natl Cancer Inst 1999;91:839-46. ment for testicular cancer. J Clin Oncol 2003;21:1513-23.
5. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: 32. Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol
a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99. 2004;22:640-7.
6. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of 33. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testic-
germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group ular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-24.
(EGCCCG): part I. Eur Urol 2008;53:478-96. 34. Moller H, Friis S, Kjaer SK. Survival of Danish cancer patients 1943-1987. Male genital organs. APMIS
7. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of Suppl 1993;33:122-36.
germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group 35. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients:
(EGCCCG): part II. Eur Urol 2008;53:497-513. focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65.
E34 CUAJ • April 2010 • Volume 4, Issue 2